Search

Allogene Therapeutics Inc

Suletud

SektorTervishoid

2.14 2.88

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.97

Max

2.17

Põhinäitajad

By Trading Economics

Sissetulek

-3.8M

-43M

Aktsiakasum

-0.18

Töötajad

150

EBITDA

-91K

-39M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+311% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

12. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-51M

735M

Eelmine avamishind

-0.74

Eelmine sulgemishind

2.14

Uudiste sentiment

By Acuity

50%

50%

164 / 342 Pingereas Healthcare

Allogene Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. juuli 2026, 23:41 UTC

Correlated Moves
Social Media
News

Micron Technology shares are lower in after-market trading, reflecting broader market pressures and concerns over a potential memory oversupply by 2028.

6. juuli 2026, 23:31 UTC

Correlated Moves
News
Social Media

Microsoft Corp announced layoffs of about 4,800 employees, primarily in its Xbox division. Shares are lower in after-market trading following the news.

6. juuli 2026, 23:26 UTC

Correlated Moves
News

Analog Devices Inc. is advancing in after-market trading, driven by a rebound in the semiconductor sector and bullish updates from UBS and Goldman Sachs.

6. juuli 2026, 23:02 UTC

Social Media
News

Vertex Pharmaceuticals shares declined in after-market hours following its $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, expected to close in 2026.

6. juuli 2026, 20:51 UTC

News
Correlated Moves

Invesco CurrencyShares Euro Trust is gaining in after-market trading, influenced by comments from Federal Reserve Governor Christopher Waller on monetary policy complexities.

6. juuli 2026, 20:07 UTC

News

Verisign shares are higher amid reported $1.1 billion in free cash flow, though concerns linger over AI advancements and upcoming contract renewals.

6. juuli 2026, 20:07 UTC

News
Social Media

Netflix Inc faces engagement issues, prompting bearish investor sentiment. The stock is trading lower amid concerns ahead of its upcoming earnings report.

6. juuli 2026, 20:07 UTC

Social Media
News
Macro Event

PayPal Holdings Inc. shares are lower as recent ISM Services data showed a slowdown in growth, with the PMI declining from the previous month.

6. juuli 2026, 20:07 UTC

Correlated Moves
News

Ethereum is advancing, supported by Tom Lee's BitMine purchasing $74 million in the asset, raising their total holdings to 5,742,237 ETH.

6. juuli 2026, 20:07 UTC

Correlated Moves
News

Bitcoin trades higher, recovering from earlier lows, amid stable cryptocurrency market conditions and concerns over inflation and interest rates. Current price is $61,750.

6. juuli 2026, 20:07 UTC

News
Correlated Moves

Bitcoin's value has risen since Sunday, reaching around $61,750. This increase occurs amid broader cryptocurrency market weakness and concerns over inflation and interest rates.

6. juuli 2026, 20:07 UTC

Social Media
News

Adobe Inc. shares are lower amid scrutiny of first-quarter results and competitive pressures from Canva and Figma, with support noted at $215.

6. juuli 2026, 20:07 UTC

News
Social Media

Apple Inc. shares are higher following an extended partnership with Broadcom for custom chips through 2031 and the reintroduction of card payments in India.

6. juuli 2026, 20:06 UTC

Event
News

Cisco Systems Inc shares are higher today as the company went ex-dividend, distributing $0.42 per share, amid positive analyst upgrades.

6. juuli 2026, 20:06 UTC

News

Ulta Beauty Inc. shares are lower amid declines in the Other Specialty Retail sub-sector and broader market weakness, trading near the bottom of its one-month range.

6. juuli 2026, 20:06 UTC

Social Media
News

Scotiabank upgraded Check Point Software to Sector Outperform, setting a price target of $185, following its 2025 ESG Report release. Shares are higher since Thursday's close.

6. juuli 2026, 20:06 UTC

News

Cintas Corp shares are lower today, continuing a broader market decline since Thursday. The stock peaked early but has trended downward since.

6. juuli 2026, 20:06 UTC

News

Cadence Design Systems reported first-quarter revenue of $1.474 billion, an 18.7% year-over-year increase, and a record backlog of $8 billion. Shares are trading higher.

6. juuli 2026, 20:06 UTC

News

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

6. juuli 2026, 20:04 UTC

News
Social Media

Tesla shares are higher today, fueled by strong second-quarter delivery figures and the positive reception of its robotaxi service in Miami.

6. juuli 2026, 20:02 UTC

News

Align Technology shares are higher today following a rating upgrade to "strong-buy" from Wall Street Zen, despite a downgrade from Weiss Ratings.

6. juuli 2026, 20:02 UTC

News

Mondelez International shares are lower amid weakness in the Packaged Foods & Meats sector. The stock remains near the lower end of its one-month trading range.

6. juuli 2026, 20:02 UTC

News
Social Media
Correlated Moves

Qualcomm's stock rises as Nvidia's CEO endorses its AI tech and Bernstein raises its price target. A partnership with Meta also boosts investor interest.

6. juuli 2026, 20:02 UTC

News
Social Media

Gilead Sciences is trading lower amid a Biotechnology sector decline, despite HSBC's upgrade to Buy and a raised price target of $155.

6. juuli 2026, 20:02 UTC

Macro Event
News

J B Hunt shares decline after Morgan Stanley downgraded the stock to Underweight, raising the price target to $200 from $190 amid sector concerns.

6. juuli 2026, 19:57 UTC

News
Social Media

Berkshire Hathaway has tripled its stake in Alphabet, boosting investor sentiment. Alphabet's inclusion in the Dow Jones further underscores its growth potential.

6. juuli 2026, 19:56 UTC

News

Natural gas is trading higher today, maintaining an upward trajectory above its 20-day moving average. ProShares Ultra Bloomberg Natural Gas has gained since Thursday's close.

6. juuli 2026, 19:53 UTC

News

Charter Communications Inc is declining amid low demand for services and stagnant returns on capital. Analysts rate the stock as "Reduce," reflecting a cautious outlook.

6. juuli 2026, 19:52 UTC

Social Media
News

Evercore ISI raised its price target on Illumina to $200, maintaining an Outperform rating. Shares are trading higher amid positive sentiment and social media discussions.

6. juuli 2026, 19:51 UTC

Social Media
News

Bank of America upgraded T-Mobile US Inc to Buy, maintaining a $220 price target, citing overstated competition concerns and the company's urban market dominance.

Võrdlus sarnastega

Hinnamuutus

Allogene Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

311% tõus

12 kuu keskmine prognoos

Keskmine 8.59 USD  311%

Kõrge 14 USD

Madal 3.85 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Allogene Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

11

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

164 / 342 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat